Time Above All Else: Pharmacodynamic Analysis of β‐Lactams in Critically Ill Patients
Autor: | Justin A. Clark, David S. Burgess, Katie B. Landmesser |
---|---|
Rok vydání: | 2021 |
Předmět: |
Tazobactam
medicine.medical_specialty Klebsiella pneumoniae Critical Illness Cefepime Microbial Sensitivity Tests beta-Lactams Meropenem Internal medicine Intensive care polycyclic compounds medicine Humans Pharmacology (medical) Piperacillin Pharmacology biology business.industry biology.organism_classification Anti-Bacterial Agents Pharmacodynamics Pseudomonas aeruginosa business Monte Carlo Method Enterobacter cloacae medicine.drug |
Zdroj: | The Journal of Clinical Pharmacology. 62:479-485 |
ISSN: | 1552-4604 0091-2700 |
DOI: | 10.1002/jcph.1977 |
Popis: | β-Lactams are the most commonly used antibiotics in intensive care units (ICUs). As critically ill patients often experience pharmacokinetic aberrations, and rates of antimicrobial resistance vary between hospital settings, reliance on tertiary sources or package labeling to guide empiric dosing often results in suboptimal β-lactam exposure. The primary objective was to identify β-lactam regimens capable of achieving ≥90% cumulative fraction of response (CFR) against 7 Gram-negative pathogens within 4 ICUs at our institution. Unit-specific minimal inhibitory concentration (MIC) distribution data was used in combination with published pharmacokinetic parameters in critically ill patients to perform Monte Carlo simulations. The percentage of time for which the unbound concentration of antibiotic remained above the MIC (%ƒT > MIC) was used as the pharmacodynamic target: 70%ƒT >MIC for cefepime, 40%ƒT > MIC for meropenem, and 50%ƒT > MIC for piperacillin/tazobactam. Regimens were modeled to determine the likelihood of achieving ≥90% CFR. Overall, intermittently dosed cefepime, meropenem, and piperacillin/tazobactam failed to achieve ≥90% CFR for every organism. Cefepime 2 g intermittent bolus every 8 hours failed to achieve ≥90% CFR for Klebsiella pneumoniae or Enterobacter cloacae despite susceptibility rates exceeding 90%. Piperacillin/tazobactam 4.5 g prolonged infusion (PI) every 6 hours achieved |
Databáze: | OpenAIRE |
Externí odkaz: |